Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly
- PMID: 16377465
- DOI: 10.1016/j.cger.2005.09.001
Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly
Abstract
Elderly patients as a group may present more of a challenge in managing warfarin therapy because of alterations in pharmacokinetics from other medications, diet, and disease; pharmacodynamic changes; increased risk for hemorrhage; and difficulty in monitoring. The elderly, however, may derive the most benefit from warfarin therapy for certain indications, such as the prevention of stroke in atrial fibrillation or recurrent events following deep venous thrombosis. Warfarin can be managed as effectively as in other populations with careful attention to these issues.
Similar articles
-
Antithrombotic therapy in atrial fibrillation.Clin Geriatr Med. 2006 Feb;22(1):155-66, x. doi: 10.1016/j.cger.2005.09.011. Clin Geriatr Med. 2006. PMID: 16377472 Review.
-
Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly.Cardiol Clin. 2008 May;26(2):157-67, v. doi: 10.1016/j.ccl.2007.12.010. Cardiol Clin. 2008. PMID: 18406992 Review.
-
Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage.Arch Neurol. 2008 Oct;65(10):1313-8. doi: 10.1001/archneur.65.10.1313. Arch Neurol. 2008. PMID: 18852344
-
Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.Thromb Haemost. 2008 Jul;100(1):14-5. doi: 10.1160/TH08-06-0344. Thromb Haemost. 2008. PMID: 18612531 No abstract available.
-
Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.Thromb Haemost. 2008 Jul;100(1):16-7. doi: 10.1160/TH08-06-0343. Thromb Haemost. 2008. PMID: 18612532 No abstract available.
Cited by
-
A population-based assessment of the drug interaction between levothyroxine and warfarin.Clin Pharmacol Ther. 2012 Dec;92(6):766-70. doi: 10.1038/clpt.2012.171. Epub 2012 Oct 24. Clin Pharmacol Ther. 2012. PMID: 23093318 Free PMC article.
-
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Ann Lab Med. 2017 Mar;37(2):180-193. doi: 10.3343/alm.2017.37.2.180. Ann Lab Med. 2017. PMID: 28029011 Free PMC article.
-
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Clin Pharmacol Ther. 2011 Oct;90(4):625-9. doi: 10.1038/clpt.2011.185. Epub 2011 Sep 7. Clin Pharmacol Ther. 2011. PMID: 21900891 Free PMC article.
-
Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy.Thromb J. 2008 Jun 3;6:6. doi: 10.1186/1477-9560-6-6. Thromb J. 2008. PMID: 18522741 Free PMC article.
-
Acute warfarin toxicity: An unanticipated consequence of amoxicillin/clavulanate administration.Am J Case Rep. 2014 Jan 27;15:45-8. doi: 10.12659/AJCR.889866. eCollection 2014. Am J Case Rep. 2014. PMID: 24494060 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical